42281-31-2 Usage
Description
3,4-Dihydro-7-methoxyspiro(cyclopentane-1,2(1H)-naphthalene)-1-one is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique chemical structure, which includes a spiro connection between a cyclopentane and a naphthalene ring, along with a methoxy group at the 7-position.
Uses
Used in Pharmaceutical Industry:
3,4-Dihydro-7-methoxyspiro(cyclopentane-1,2(1H)-naphthalene)-1-one is used as an intermediate in the synthesis of rac-14-epi-Dextromethorphan (D299440), which is an analog of Dextromethorphan (D299445). Dextromethorphan is an antitussive compound with analgesic properties, commonly used in cough medication formulations to suppress coughing.
In the synthesis process, 3,4-Dihydro-7-methoxyspiro(cyclopentane-1,2(1H)-naphthalene)-1-one plays a vital role in creating the desired pharmacological effects of the final product, rac-14-epi-Dextromethorphan. This intermediate compound is essential for the development of new and improved antitussive and analgesic medications, potentially offering better efficacy and reduced side effects for patients suffering from cough and pain.
Check Digit Verification of cas no
The CAS Registry Mumber 42281-31-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,2,2,8 and 1 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 42281-31:
(7*4)+(6*2)+(5*2)+(4*8)+(3*1)+(2*3)+(1*1)=92
92 % 10 = 2
So 42281-31-2 is a valid CAS Registry Number.
42281-31-2Relevant articles and documents
OCTAHYDROPHENANTHRENE DERIVATIVES
-
, (2008/06/13)
Compounds of the formula: STR1 wherein R 1 and R 2 each individually are hydrogen or lower alkyl optionally substituted by aryl or C 3-6-cycloalkyl;R 4 and R 5 either both are hydrogen or both are halogen or one is hydrogen and the other is halogen, hydroxy, lower alkoxy, aryloxy or amino; and R. sup.3 is hydrogen or, where no primary or secondary amino group is present, alkanoyl;with the proviso that all the groups R 1 through R 5 cannot simultaneously be hydrogen; as well as pharmaceutically acceptable salts of compounds of formula I with acids have valuable pharmacodynamic properties as non-competitive NMDA antagonists and can accordingly be used as neuroprotectives.
Synthetic morphinans and hasubanans. IV. Total synthesis of 3,14 dihydroxyisomorphinans, 3 methoxy Δ8,14 morphinans, and 9α hydroxy 3 methoxyhasubanan
Monkovic,Wong,Belleau,et al.
, p. 2515 - 2523 (2007/10/05)
-
